date,title,source
Oct-18-18,Translate Bio to Present Preclinical Data Supporting MRT5005 at the 32nd Annual North American Cystic Fibrosis Conference,GlobeNewswire
Nov-01-18,Translate Bio to Participate in Upcoming Investor Conferences,GlobeNewswire
Nov-08-18,Translate Bio Announces Third Quarter 2018 Financial Results and Reviews Recent Highlights,GlobeNewswire
Nov-23-18,Do Institutions Own Shares In Translate Bio Inc (NASDAQ:TBIO)?,Simply Wall St.
Dec-04-18,Translate Bio Expands Patent Portfolio with Newly Issued U.S. Patent Relating to Its Messenger RNA (mRNA) Therapeutics Platform (MRT),GlobeNewswire
Dec-07-18,[$$] Moderna IPO Marks Milestone for New Biotech Market,The Wall Street Journal
Dec-20-18,"DAFNA Capital Management Return, AUM and Holdings",Insider Monkey
Jan-03-19,"Translate Bio Appoints Robert Meyer, MD, to its Board of Directors",GlobeNewswire
Jan-03-19,Translate Bio Advances Programs in Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency,GlobeNewswire
Jan-04-19,[$$] Translate Bio Shares Surge,The Wall Street Journal
Jan-22-19,Translate Bio Announces FDA Clinical Hold on Investigational New Drug Application (IND) for MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency,GlobeNewswire
